Debut Biotech

OverviewSuggest Edit

Debut Biotech is a biotechnology company that focuses on developing a platform for cell-free biocatalysis. It specializes in creating a range of immobilized enzymes for use in manufacturing systems: biomanufacturing cartridges, fermentation, immobilization of cells and enzymes and enzymes for pharmaceutical production and modification.


Latest Updates

Employees (est.) (May 2020)11

Key People/Management at Debut Biotech

Joshua Britton

Joshua Britton

Co-Founder and CEO
Brady Beauchamp

Brady Beauchamp

Co-Founder and COO
Gregory Weiss

Gregory Weiss

Co-Founder and Scientific Advisor
Nick Brideau

Nick Brideau

Director, Molecular Biology
Ali Emileh

Ali Emileh

Director, Protein Engineering
Show more

Debut Biotech Financials and Metrics

Summary Metrics

Founding Date


Debut Biotech total Funding

$2.6 m

Debut Biotech latest funding size

$2.60 m

Time since last funding

5 months ago

Debut Biotech investors

Debut Biotech's latest funding round in January 2020 was reported to be $2.6 m. In total, Debut Biotech has raised $2.6 m
Show all financial metrics

Debut Biotech Online and Social Media Presence

Embed Graph

Debut Biotech Frequently Asked Questions

  • When was Debut Biotech founded?

    Debut Biotech was founded in 2019.

  • Who are Debut Biotech key executives?

    Debut Biotech's key executives are Joshua Britton, Brady Beauchamp and Gregory Weiss.

  • How many employees does Debut Biotech have?

    Debut Biotech has 11 employees.

  • Who are Debut Biotech competitors?

    Competitors of Debut Biotech include Phitonex, Tenaya Therapeutics and FluoroFinder.